Navigation Links
Advair's Patient Share in Newly Diagnosed Asthma Patients is Declining
Date:12/1/2008

WALTHAM, Mass., Dec. 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that patient share for GlaxoSmithKline's Advair is declining in all lines of therapy for newly diagnosed asthma patients.

The new report entitled Treatment Algorithms in Asthma shows a reduction in Advair use in first-, second- and third-lines of therapy to 12.2 percent, 13.6 percent, and 14.6 percent, respectively when compared to the 2007 analysis that showed Advair was prescribed in 13.9 percent, 19.3 percent and 16.5 percent of first-, second- and third-line patients, respectively.

The decline in Advair's patient share is due to several factors: physicians' (particularly primary care physicians [PCPs]) increasing use of Merck's Singulair first-line, pushing Advair to later lines of therapy; specialists favoring newer once-daily inhaled corticosteroids (ICSs) with more favorable side-effect profiles in patients with less-severe disease prior to progressing to a long-acting beta2 agonist (LABA)/ICS combination; and physician movement towards using AstraZeneca's newly launched Symbicort as an alternative to Advair in later lines of therapy.

The report also finds that surveyed physicians will continue to use Singulair first-line regardless of March 2008 media reports linking the drug to behavior/mood changes and suicidality (suicidal thinking and behavior).

"The majority of pulmonologists, allergists and PCPs we surveyed told us that these media reports have had no effect on their treatment practice," added Dr. Westphal. "However, more surveyed allergists and PCPs told us that in the next two years they are likely to monitor their Singulair patients with increased vigilance, which likely reflects their treatment of a higher percentage of patients under the age of 18 compared with surveyed pulmonologists."

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    Natalia Morales                 Elizabeth Marshall
    Decision Resources              Decision Resources, Inc.
    781-296-2691                    781-296-2563
    nmorales@dresources.com         emarshall@dresources.com

'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Novel Techniques Offers New Freedom to Patients with Parkinson's Disease, Epilepsy, Dystonia, and Tremor
2. Prescription for patient safety
3. Transfusing Anemic Cancer Patients Boosts Clot Risk
4. Major North American breakthrough for dialysis patients
5. Blue Cross/Blue Shield Christmas Gift to Federal Employees: Surprise, Were Cutting Your Benefits!; Patients, Doctors and Health Care Providers Outraged
6. Singapore Caters to Middle East Medical Travelers with Arabic Version of Patients Beyond Borders-Singapore Edition
7. Pulmonary Hypertension Treated with Stem Cells : International Medical Team Announces Patient Results in Adult Stem Cell Clinical Study for Pulmonary Hypertension
8. Disclosure of medication can save a patients life
9. Steroid Inhalers Raise Pneumonia Risk for Lung Disease Patients
10. Doctors Receive Bonuses for Providing Optimal Care to Patients Through Bridges to Excellence
11. Transfusions increase clot risk in hospitalized cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... 2017 , ... STATEMENT OPPOSING PRESIDENT DONALD TRUMP’S 2018 BUDGET ... budget, “A New Foundation for American Greatness—President's Budget FY 2018,” because it is ... populations, undermines productivity, and destroys the social safety net needed by hardworking but ...
(Date:5/24/2017)... ... May 24, 2017 , ... Medic CE , a Career Step ... Pediatric Septic Shock” hosted by the Journal of Emergency Medical Services (JEMS). The free ... will be presented by Captain Rommie Duckworth, LP, a career fire captain as well ...
(Date:5/24/2017)... ... May 24, 2017 , ... Rob Lowe is a sought after actor, ... Television. “Informed” brings the public important topics from all aspects of life, and a ... and issues surrounding feet and ankles. , Podiatry is essential to people’s overall well-being, ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... (PVDF) based sleep diagnostics sensors, announced today it had completed the first phase ... a mix of domestic and rest of world (ROW) authorized dealers specializing in ...
(Date:5/23/2017)... NEW YORK, NY (PRWEB) , ... May 23, ... ... decision makers in the pharmaceutical and medical device sectors, today announced the winners ... • Transformers • Entrepreneurs) represent the most influential people in the healthcare industry ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... COTTAGE, N.Y. , May 22, 2017 /PRNewswire/ ... antiviral treatment Gene-Eden-VIR/Novirin, announces the launch of a ... plain English, the results of a clinical study ... one year treatment with Gene-Eden-VIR/Novirin in individuals suffering ... important to note that there are no other ...
(Date:5/15/2017)... ATLANTA , May 15, 2017  Amy Baxter ... the industry leader in noninvasive pain relief, was awarded ... MM&M magazine. Baxter was recognized at the MM&M ... New York City on May 10, ... helping the biopharma industry go "beyond the pill."  ...
(Date:5/10/2017)... MARLBOROUGH, Mass., May 10, 2017 Hologic, Inc. ... financial results for the fiscal second quarter ended April ... (EPS) of $1.84 increased 666.7% compared to the prior ... business resulted in a significant gain, while non-GAAP diluted ... increased 3.2%, or 3.8% in constant currency terms.  Excluding ...
Breaking Medicine Technology: